The U.S. Food and Drug Administration has declined to approve Camurus' drug for the treatment of a rare hormonal disorder due ...

The regulator cited deficiencies at a third-party manufacturing facility. Camurus is seeking approval for its ...

The FDA issued a complete response letter (CRL) to Camurus, dealing a setback to the Swedish drugmaker’s efforts to bring its ...

The FDA handed a CRL to the Swedish biotech Camurus for its hormone disorder therapy over “facility-related deficiencies” at ...

CAM2029 is a novel depot formulation of octreotide, a somatostatin analogue, administered subcutaneously once monthly.

In a summary of current health news: the CDC investigates bird flu in Washington, David Joyner becomes CVS CEO, China tackles ...

In a phase III trial of adults with type 2 diabetes with heart disease and/or chronic kidney disease, oral semaglutide ...

Jefferies analyst Brian Balchin maintained a Buy rating on Camurus AB (CAMRF – Research Report) today and set a price target of ...

Munters Group AB posted the largest decline among large stocks during the session, plunging 11.0%, followed by Camurus AB shares, which declined 9.8%. Shares of Lifco AB Series B fell 5.8%.

**NM signifies a non meaningful value. A dash signifies the data is not available.

Delhi HC closed contempt proceedings against Wikipedia after the platform globally removed a defamatory page. The court criticized Wikipedia for refusing to disclose user identities responsible ...

The Russian leader hopes to use the meeting of the so-called BRICS group, which includes China and India, as a counterweight to the West. By Valerie Hopkins and David Pierson The former U.S ...